Seong Lin Khaw

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6742765/publications.pdf

Version: 2024-02-01

19 papers	3,839 citations	840776 11 h-index	839539 18 g-index
19 all docs	19 docs citations	19 times ranked	5774 citing authors

#	Article	IF	Citations
1	SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia. Blood Advances, 2022, 6, 2373-2387.	5.2	4
2	Two novel cases of NUTM1â€rearranged Bâ€cell acute lymphoblastic leukaemia presenting with highâ€risk features. British Journal of Haematology, 2022, 196, 1407-1411.	2.5	4
3	Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discovery, 2021, 11, 1440-1453.	9.4	137
4	Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab. Pediatric Blood and Cancer, 2021, 68, e28922.	1.5	16
5	Cycling without brakes lets ALL escape. Blood, 2021, 138, 1912-1913.	1.4	0
6	Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2020, 136, 12-13.	1.4	2
7	The first report of pediatric patients with solid tumors treated with venetoclax.. Journal of Clinical Oncology, 2020, 38, 10524-10524.	1.6	3
8	Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles. Blood, 2020, 136, 30-31.	1.4	4
9	Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2019, 134, 285-285.	1.4	24
10	Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2018, 132, 3966-3966.	1.4	5
11	Open-label, dose-escalation, phase 1 study of venetoclax in combination with navitoclax and chemotherapy in patients with relapsed acute lymphoblastic leukemia.. Journal of Clinical Oncology, 2018, 36, TPS10575-TPS10575.	1.6	1
12	Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood, 2016, 128, 1382-1395.	1.4	148
13	BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells. Leukemia, 2016, 30, 1531-1541.	7.2	29
14	Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia, 2014, 28, 1207-1215.	7.2	79
15	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Medicine, 2013, 19, 202-208.	30.7	2,426
16	Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease. Journal of Clinical Oncology, 2012, 30, 488-496.	1.6	719
17	Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies. Pathology, 2011, 43, 525-535.	0.6	36
18	The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs. Molecular Pharmacology, 2010, 77, 483-494.	2.3	111

#	Article	IF	Citations
19	The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia, 2009, 23, 2034-2041.	7.2	91